CSL Cuts Profit Outlook, Flags $5 Billion in New Impairments

CSL Ltd. has cut its profit outlook and flagged $5 billion in new impairments. The company's stock has plateaued since 2020 after delivering a 750% return for investors in the decade before the Covid-19 pandemic. This change affects Australia's largest biotechnology company.